Patents by Inventor Irving L. Weissman

Irving L. Weissman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti SIRP-alpha Antibodies and Bi-specific Macrophage Enhancing Antibodies
    Publication number: 20170073414
    Abstract: Anti-SIRP? antibodies, including multi-specific anti-SIRP? antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRP? and can block the interaction of CD47 on one cell with SIRP? on a phagocytic cell. Antibodies that are bispecific for SIRP? and a second antigen are termed Bi-specific Macrophage Enhancing (BiME) antibodies and have emergent properties. The subject anti-SIRP? antibodies find use in various therapeutic methods. Embodiments of the disclosure include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the anti-SIRP? antibodies; and cell lines that produce the antibodies. Also provided are amino acid sequences of exemplary anti-SIRP? antibodies.
    Type: Application
    Filed: March 11, 2015
    Publication date: March 16, 2017
    Inventors: Kipp Andrew Weiskopf, Aaron Michael Ring, Jens-Peter Volkmer, Irving L. Weissman, Nan Guo Ring
  • Selective Immunodepletion of Endogenous Stem Cell Niche for Engraftment
    Publication number: 20170066834
    Abstract: The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. Aspects of the present invention are based on the discovery that the depletion of the endogenous stem cell niche facilitates efficient engraftment of stem cells into that niche. In particular, the present invention combines the use of selective ablation of endogenous stem cells, in combination with the administration to the recipient of exogenous stem cells, resulting in efficient, long-term engraftment and tolerance.
    Type: Application
    Filed: July 15, 2016
    Publication date: March 9, 2017
    Inventors: Irving L. Weissman, Agnieszka Czechowicz, Deepta Bhattacharya, Daniel Kraft
  • High affinity PD-1 agents and methods of use
    Patent number: 9562087
    Abstract: High affinity PD-1 mimic polypeptides are provided, which (i) comprise at least one amino acid change relative to a wild-type PD-1 protein; and (ii) have an increased affinity for PD-L1 relative to the wild-type protein. Compositions and methods are provided for modulating the activity of immune cells in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity PD-1 mimic polypeptide, which blocks the physiological binding interaction between PD-1 and its ligand PD-L1 and/or PD-L2.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: February 7, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Aaron Michael Ring, Andrew Kruse, Aashish Manglik, Irving L. Weissman, Roy Louis Maute, Melissa N. McCracken, Sydney Gordon
  • High affinity PD-1 agents and methods of use
    Patent number: 9546206
    Abstract: High affinity PD-1 mimic polypeptides are provided, which (i) comprise at least one amino acid change relative to a wild-type PD-1 protein; and (ii) have an increased affinity for PD-L1 relative to the wild-type protein. Compositions and methods are provided for modulating the activity of immune cells in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity PD-1 mimic polypeptide, which blocks the physiological binding interaction between PD-1 and its ligand PD-L1 and/or PD-L2.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: January 17, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Aaron Michael Ring, Andrew Kruse, Aashish Manglik, Irving L. Weissman, Roy Louis Maute, Melissa N. McCracken, Sydney Gordon
  • Targeted Therapy for Small Cell Lung Cancer
    Publication number: 20160333093
    Abstract: Methods are provided for treatment of lung cancers, particularly small cell lung cancer with targeted therapy, which optionally includes an agent that selectively blocks CD47 binding to SIRP?.
    Type: Application
    Filed: January 8, 2015
    Publication date: November 17, 2016
    Inventors: Kipp Andrew Weiskopf, Julien Sage, Irving L. Weissman
  • Methods for manipulating phagocytosis mediated by CD47
    Patent number: 9493575
    Abstract: Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: November 15, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Siddhartha Jaiswal, Irving L. Weissman, Ravindra Majeti, Mark P. Chao
  • HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODIES TO CD47
    Publication number: 20160304609
    Abstract: Humanized or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD47, and find use in various therapeutic methods. Preferred are non-activating antibodies. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid sequences of the antibodies.
    Type: Application
    Filed: June 7, 2016
    Publication date: October 20, 2016
    Inventors: Jie Liu, Irving L. Weissman, Ravindra Majeti
  • Therapeutic and Diagnostic Methods for Manipulating Phagocytosis Through Calreticulin and Low Density Lipoprotein-Related Receptor
    Publication number: 20160289326
    Abstract: Therapeutic and diagnostic methods are provided, which methods relate to the expression of calreticulin on cancer cells and hematopoietic cells.
    Type: Application
    Filed: June 3, 2016
    Publication date: October 6, 2016
    Inventors: Mark P. Chao, Rachel Weissman-Tsukamoto, Siddhartha Jaiswal, Ravindra Majeti, Irving L. Weissman
  • Methods for manipulating phagocytosis mediated by CD47
    Patent number: 9399682
    Abstract: Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: July 26, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Siddhartha Jaiswal, Irving L. Weissman, Ravindra Majeti, Mark P. Chao
  • Methods of Manipulating Phagocytosis Mediated by CD47
    Publication number: 20160200816
    Abstract: Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.
    Type: Application
    Filed: February 26, 2016
    Publication date: July 14, 2016
    Inventors: Siddhartha Jaiswal, Irving L. Weissman, Ravindra Majeti, Mark P. Chao
  • MODULATION OF EFFEROCYTOSIS PATHWAYS FOR TREATMENT OF ATHEROSCLEROTIC DISEASE
    Publication number: 20160194406
    Abstract: Smooth muscle cells (SMC) from subjects carrying at least one 9p21 risk factor, can be resistant to efferocytosis, leading to the retention of such cells in the necrotic core of atherosclerotic plaque. In the methods of the invention, an agent that increases efferocytosis of cellular components of coronary plaque, including efferocytosis of apoptotic smooth muscle cells, is administered to the subject in a dose and for a period of time effective to stabilize, prevent or reduce atherosclerotic plaque in the individual.
    Type: Application
    Filed: September 15, 2014
    Publication date: July 7, 2016
    Inventors: Nicholas J. Leeper, Irving L. Weissman
  • Humanized and chimeric monoclonal antibodies to CD47
    Patent number: 9382320
    Abstract: Humanized or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD47, and find use in various therapeutic methods. Preferred are non-activating antibodies. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid sequences of the antibodies.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: July 5, 2016
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Jie Liu, Irving L. Weissman, Ravindra Majeti
  • Methods of Manipulating Phagocytosis Mediated by CD47
    Publication number: 20160176978
    Abstract: Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.
    Type: Application
    Filed: February 26, 2016
    Publication date: June 23, 2016
    Inventors: Siddhartha Jaiswal, Irving L. Weissman, Ravindra Majeti, Mark P. Chao
  • Methods of Manipulating Phagocytosis Mediated by CD47
    Publication number: 20160176976
    Abstract: Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.
    Type: Application
    Filed: February 26, 2016
    Publication date: June 23, 2016
    Inventors: Siddhartha Jaiswal, Irving L. Weissman, Ravindra Majeti, Mark P. Chao
  • Use of Anti-CD47 Agents to Enhance Immunization
    Publication number: 20160144009
    Abstract: Methods are provided for enhancing immunization strategies by manipulation, e.g. in vitro manipulation, of phagocytic antigen presenting cells. In the methods of the invention, phagocytic antigen presenting cells (phAPC) are incubated with a particulate antigen in the presence of an anti-CD47 agent in a dose and for a period of time sufficient to allow the phAPC to phagocytose the particulate antigen, which process generates a “loaded” phAPC. The loaded phAPC is contacted with a population of T cells matched for at least one major histocompatibility locus with the phAPC, where the T cells are stimulated after contacting to generate an effector response against an epitope or epitopes present on the particulate antigen.
    Type: Application
    Filed: April 23, 2014
    Publication date: May 26, 2016
    Inventors: Diane Tseng, Jens-Peter Volkmer, Kipp Andrew Weiskopf, Stephen Willingham, Irving L. Weissman
  • Methods for Determining Responsiveness to an Anti-CD47 Agent
    Publication number: 20160069898
    Abstract: Methods and kits are provided for determining whether an individual is responsive to an anti-CD47 agent and for determining whether an individual is maintaining responsiveness to an anti-CD47 agent by assaying biological samples for the level of at least one biomarker in a biological sample.
    Type: Application
    Filed: May 16, 2014
    Publication date: March 10, 2016
    Inventors: Kipp Andrew Weiskopf, Irving L. Weissman
  • Markers of Acute Myeloid Leukemia Stem Cells
    Publication number: 20160060342
    Abstract: Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.
    Type: Application
    Filed: October 29, 2015
    Publication date: March 3, 2016
    Inventors: Ravindra Majeti, Irving L. Weissman
  • HIGH AFFINITY PD-1 AGENTS AND METHODS OF USE
    Publication number: 20160052990
    Abstract: High affinity PD-1 mimic polypeptides are provided, which (i) comprise at least one amino acid change relative to a wild-type PD-1 protein; and (ii) have an increased affinity for PD-L1 relative to the wild-type protein. Compositions and methods are provided for modulating the activity of immune cells in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity PD-1 mimic polypeptide, which blocks the physiological binding interaction between PD-1 and its ligand PD-L1 and/or PD-L2.
    Type: Application
    Filed: November 3, 2015
    Publication date: February 25, 2016
    Inventors: Aaron Michael Ring, Andrew Kruse, Aashish Manglik, Irving L. Weissman, Roy Louis Maute, Melissa N. McCracken, Sydney Gordon
  • HIGH AFFINITY PD-1 AGENTS AND METHODS OF USE
    Publication number: 20160039903
    Abstract: High affinity PD-1 mimic polypeptides are provided, which (i) comprise at least one amino acid change relative to a wild-type PD-1 protein; and (ii) have an increased affinity for PD-L1 relative to the wild-type protein. Compositions and methods are provided for modulating the activity of immune cells in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity PD-1 mimic polypeptide, which blocks the physiological binding interaction between PD-1 and its ligand PD-L1 and/or PD-L2.
    Type: Application
    Filed: August 7, 2015
    Publication date: February 11, 2016
    Inventors: Aaron Michael Ring, Andrew Kruse, Aashish Manglik, Irving L. Weissman, Roy Louis Maute, Melissa N. McCracken, Sydney Gordon
  • Methods For Manipulating Phagocytosis Mediated By CD47
    Publication number: 20160009814
    Abstract: Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.
    Type: Application
    Filed: July 14, 2015
    Publication date: January 14, 2016
    Inventors: Siddhartha Jaiswal, Irving L. Weissman, Ravindra Majeti, Mark P. Chao